Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2006

View Archived Issues

Glenmark presents new CB2 agonists as promising antihyperalgesic candidates

Silenor effective at inducing and maintaining sleep in transient insomnia patients

Phase I results warrant abagovomab's further evaluation

GPCR inhibitor blocks cancer growth, induces apoptosis and synergizes with anticancer drugs

Sazetidine-A: a new desensitizing nicotinic ligand

Recent patents report new treatment strategies for respiratory disorders

Therapeutic agents for arteriosclerosis, hypertension, etc. disclosed in recent patents

Recent patent literature discloses novel analgesic agents

Orexo receives license payment from Endo for Rapinyl

Acadia to support new substance abuse startup company Abbey

Enrollment over half complete in phase IIb trial of CF-101 in rheumatoid arthritis

Phase II study of HCV-796 begins dosing

Preliminary three-month findings from endometriosis study of Proellex

MVA-BN polytope vaccine begins new trials in Europe

New trial studies HuMax-EGFr with chemoradiation for head and neck cancer

Dharma's iontophoretic drug delivery system shows promise in phase I study

EvoGenix completes first project under GSK collaboration

ASF-1057 begins phase IIb studies for seborrheic dermatitis

Alantos and Servier collaborate on DPP-IV inhibitor ALS-2-0426

Amgen completes acquisition of Avidia

Termination of Takeda and BioNumerik's Tavocept agreement

Renovo: pipeline update

Aridol approved in Sweden

FDA approves Tyzeka for chronic hepatitis B

Promising preliminary results for ASF-1096 formulation in cutaneous lupus erythematosus

New clinical study of levetiracetam for Tourette syndrome

Memory Pharmaceuticals discloses MEM-3454 preclinical data at the SfN meeting

The glycine transporter-1 inhibitor SSR-103800 shows promise in animal models of schizophrenia

Targeting Fc receptors: a promising approach for the treatment of B-cell malignancies

Mahonia aquifolium alkaloids may be useful against Malassezia skin infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...